

## OliX announces clinical candidate for Geographic Atrophy treatment

29 January 2019 | News

**OLX10020 has completed preliminary safety evaluation.**



OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, has announced the nomination of OLX10020 as a clinical candidate for the treatment of Geographic Atrophy (GA), which is the most severe and advanced form of dry Age-related Macular Degeneration (AMD).

OLX10020 targets an undruggable gene involved in GA, identified by Dr. Jayakrishna Ambati, a professor at University of Virginia, School of Medicine. Results from animal studies support that OLX10020 can specifically target patients with GA among dry AMD patients. Furthermore, OLX10020 has been proved effective in wet AMD animal models, indicating that it is a potential first-in-class drug which can treat both dry and wet AMDs.

OLX10020 has completed preliminary safety evaluation and GLP toxicology studies will be commenced soon at Covance (Madison, WI, USA). An IND application is planned to be submitted to the FDA to initiate a Phase 1 within this year.